Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hensel

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|December 16, 2006
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysisUlrich J M Mey, Attilio Olivieri, Katjana S Orlopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
TP53 mutation and survival in chronic lymphocytic leukemiaThorsten Zenz, Barbara Eichhorst, Raymonde Busch, et al.
Leukemia & Lymphoma|July 1, 2016
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemiaNadine Kutsch, Raymonde Busch, Jasmin Bahlo, et al.
Blood|October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaHolger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Scandinavian Journal of Infectious Diseases|July 24, 2013
HIV-associated lung cancer: survival in an unselected cohortChristian Hoffmann, Fabienne Kohrs, Michael Sabranski, et al.
British Journal of Haematology|October 10, 2015
Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trialMathias Witzens-Harig, Axel Benner, Fabienne McClanahan, et al.
Blood|October 13, 2005
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Georg Hopfinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupStephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Leukemia Research|May 12, 2021
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analoguesMarco M Bühler, Junyan Lu, Sebastian Scheinost, et al.
Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|December 16, 2006
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysisUlrich J M Mey, Attilio Olivieri, Katjana S Orlopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
TP53 mutation and survival in chronic lymphocytic leukemiaThorsten Zenz, Barbara Eichhorst, Raymonde Busch, et al.
Leukemia & Lymphoma|July 1, 2016
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemiaNadine Kutsch, Raymonde Busch, Jasmin Bahlo, et al.
Blood|October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaHolger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Scandinavian Journal of Infectious Diseases|July 24, 2013
HIV-associated lung cancer: survival in an unselected cohortChristian Hoffmann, Fabienne Kohrs, Michael Sabranski, et al.
British Journal of Haematology|October 10, 2015
Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trialMathias Witzens-Harig, Axel Benner, Fabienne McClanahan, et al.
Blood|October 13, 2005
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Georg Hopfinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study GroupStephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, et al.
Leukemia Research|May 12, 2021
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analoguesMarco M Bühler, Junyan Lu, Sebastian Scheinost, et al.
Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.
Pageof 6